← Evidence map

ArticleCureus2025

Inequalities in Drug Access for Advanced Melanoma: The Prognostic Impact Resulting From the Approval Delay of the Combined Ipilimumab/Nivolumab Treatment in Portugal.

Diana Baptista da Mata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Inequalities in Drug Access for Advanced Melanoma: The Prognostic Impact Resulting From the Approval Delay of the Combined Ipilimumab/Nivolumab Treatment in Portugal. | OpenQuestion